What happens between “your own cells” and “back to you”? Inside the medical journey from assessment and mobilisation to apheresis and collection.
Once the idea of using your own cells makes sense, the next question is usually practical: what actually happens?
An autologous pathway is not a single procedure. It is a sequence of medical decisions that begins before anything is collected.
First: should the process begin at all?
Medical history, current health, medications and relevant investigations help determine whether proceeding is appropriate. The question is not simply whether cells can be collected, but whether collection makes sense for this individual, at this time and for the intended purpose.
Mobilisation
Blood-forming stem cell and progenitor cells are found predominantly within the bone marrow. A mobilisation step can increase the number circulating in peripheral blood so that collection becomes possible. Human studies demonstrate that this response can vary substantially between individuals. [2] At the appropriate collection window, the next stage begins.
Apheresis
Apheresis is not simply a larger blood draw. Blood circulates through a specialised system that separates the cellular component being collected while returning the remaining blood components to the individual. It is an established method for peripheral-blood progenitor-cell collection. [3]
The collected material is a blood-derived cellular product containing hematopoietic stem and progenitor cells alongside other autologous blood-cell populations; it should not be imagined as a vial of one purified cell type.
Where specialist expertise matters
Mobilisation and apheresis sit within a specialised area of medicine involving blood components and cellular collection.
At Hertitude, cases involving autologous blood-derived cell collection are medically reviewed by a specialist in transfusion medicine with direct experience in apheresis and autologous blood-cell collection.
The machine performs the collection. Medical judgement shapes the process around it.
After collection
What happens after collection depends on the medical plan, intended use and the clinical and regulatory framework that applies to the individual case.
The important point is that an individual process does not create an individual guarantee. Different people may have different experiences, and biological plausibility should not be presented as certainty of clinical benefit. [4]
Understanding the journey is not meant to make the decision feel inevitable. It is meant to make the decision informed.
Selected references
[1] National Cancer Institute. Definition of “autologous”: taken from an individual’s own tissues, cells, or DNA. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/autologous
[2] Liles WC, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood. 2003;102(8):2728-2730. PMID: 12855591.
[3] AABB. Hematopoietic Stem Cells / Peripheral Blood Progenitor Cells: collection by apheresis. https://www.aabb.org/blood biotherapies/biotherapies/facts-about-cellular-therapies/hematopoietic-stem-cells
[4] International Society for Stem Cell Research (ISSCR). Guidelines for Stem Cell Research and Clinical Translation; Communications and Clinical Translation sections. 2025. https://www.isscr.org/guideline
Written by Parintorn Nakdee 69278
Transfusion Medicine
Medical Wellness by Hertitude Clinic
